Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

ABSTRACT: Immunotherapy with gene engineered CAR and TCR transgenic T-cells is a transformative treatment in cancer medicine. There is a rich pipeline with target antigens and sophisticated technologies that will enable establishing this novel treatment not only in rare hematological malignancies, but also in common solid tumors. The T2EVOLVE consortium is a public private partnership directed at accelerating the preclinical development of and increasing access to engineered T-cell immunotherapies for cancer patients. A key ambition in T2EVOLVE is to assess the currently available preclinical models for evaluating safety and efficacy of engineered T cell therapy and developing new models and test parameters with higher predictive value for clinical safety and efficacy in order to improve and acceler

SUBMITTER: Guedan S 

PROVIDER: S-EPMC9115015 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature